WHO backs GLP-1 drugs for obesity care
On Monday, the World Health Organization issued new clinical guidelines recommending GLP-1 therapies for long‑term treatment of obesity in adults (excluding pregnant women) and pairing them with intensive behavioral therapy; both recommendations are conditional due to limited long‑term data, costs and other factors. WHO urged urgent action on manufacturing, affordability and health‑system readiness, warning GLP‑1s may reach fewer than 10% of eligible patients by 2030, and noted it added GLP‑1s to its Essential Medicines List for diabetes in high‑risk groups in September.
📌 Key Facts
- WHO issues conditional recommendation for adult long‑term GLP‑1 use in obesity, excluding pregnancy.
- WHO also conditionally recommends combining GLP‑1s with intensive diet/exercise behavioral therapy.
- WHO calls for expanded manufacturing and affordability; projects <10% eligible access by 2030.
📊 Relevant Data
In the United States, Non-Hispanic Black adults have high obesity prevalence, with 38 areas (states, territories, or DC) reporting 35% or higher rates, compared to 34 for Hispanic adults, 30 for Non-Hispanic American Indian or Alaska Native adults, 16 for Non-Hispanic White adults, and 0 for Non-Hispanic Asian adults.
Globally, causes of obesity include genetic variants alongside obesogenic environments and psycho-social factors.
Obesity and overweight — World Health Organization (WHO)
Genetic studies indicate that ancestry-specific polygenic risk scores improve prediction of obesity risk across different racial and ethnic groups, addressing limitations of European-centric models.
Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025 — PMC
Gene-environment interactions involving genes like FTO and MC4R show that high genetic risk can amplify weight gain in environments with poor diet and activity levels.
Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025 — PMC
Genetic variants in GLP-1R, such as SNPs rs3765467 and rs10305492, modestly affect responses to GLP-1 receptor agonists, influencing insulin secretion and gastric emptying.
Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025 — PMC